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Objective To evaluate whether the effect of acetazolamide on piperacillin's aqueous humor concentrations
observed in animals exists also in humans for ceftazidime, cefotaxime, ceftriaxone and aztreonam.
Methods One hundred and eighty-eight patients undergoing eye cataract surgery were randomly allocated to
receive intravenous ceftazidime, cefotaxime, aztreonam or ceftriaxone with (subgroup A) or without (subgroup
B) concomitant oral administration of acetazolamide. Antibiotic concentrations in serum and the aqueous
humor, simultaneously sampled during the operation, were measured using an agar well diffusion technique, and
the ratios ofthe concentrations ofaqueous humor to serum were calculated and compared. Statistical analysis was
performed by using the paired t-test.
Results Mean aqueous humor ceftazidime concentrations at 2, 4 and 6 h were 24.65, 16.4 and 8.6 mg/L
(subgroup A), and 4.26, 8.66 and 5.61 mg/L (subgroup B). Corresponding concentrations of cefotaxime were
1.75, 1.0 and 0.77 mg/L (subgroup A), and 1.11, 0.81 and 0.58 mg/L (subgroup B), and ofaztreonam 6.9,5.84
and 3.61 mg/L (subgroup A), and 3.38,2.57 and 1.48 mg/L (subgroup B). Ceftriaxone concentrations at 2,4,6
and 12 h were 1.78, 1.49, 1.57 and 1.41 mg/L (subgroup A), and 1.35, 0.95,1.08 and 0.85 mg/L (subgroup B).
The differences in aqueous humor concentrations when acetazolamide was administered were statistically
significant (P < 0.05), with the exception of ceftazidime 6 h, cefotaxime 6 hand ceftriaxone 2 h.
Conclusions Although acetazolamide resulted in statistically significant increases in the aqueous humor
concentrations of all the antibiotics tested, this effect was most marked for ceftazidime.
Keywords Endophthalmitis, acetazolamide, cephalosporins, ceftazidime, cefotaxime, ceftriaxone, aztreonam,
pharmacokinetics
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INTRODUCTION
Bacterial endophthalmitis is a suppurative inflammation of the
intraocular contents in which not all the layers of the globe are
affected and in which the eye does not rupture. Endophthal-
mitis may be either exogenous, following penetrating wounds,
either accidental or surgical, or the insertion of a foreign body,
or endogenous, resulting either from a distant focus ofinfection
through hematogenous spread or from a nearby focus by direct
spread [1]. It is a severe infection, as the probability of resulting
blindness is high. Coagulase-negative staphylococci are now the
most commouly involved pathogens, followed by Staphylococcus
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aureus, Pseudomonas aeruginosa, other Gram-negative rods and
streptococci. Moreover, bacteria previously not considered as
pathogens, such as Bacillus cereus (mostly associated with
trauma), Propiobacterium ames, and fungi, are now being isolated
with increasing frequency.
Despite the development of new and potent antibiotics in
recent years, it is now clear that fully efficient therapy for such
infections does not exist because of the poor penetration of
systemic antibiotics into the intraocular compartments, due to
the existing barriers [2,3]. The situation is further complicated
by the fact that resistance has already emerged in the commouly
implicated pathogens, even to the newer agents. While some
newer and promising antibiotics active against Gram-positive
cocci, such as linezolid and synercid, have recently been
introduced, it still holds true that such drugs active against
Gram-negative rods will not be available in the near future [4].
One solution could be to maximize the benefit from the
existing antimicrobials by improving their eye kinetics. Previous
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Table 1 Demographic characteristics of our patients
Group I (Ceftazidime) Group II (Cefotaxime) Group III (Ceftriaxone) Aztreonam
A B A B A B A B
No. of patients 31 15 22 22 25 24 26 23
Male 21 10 14 11 12 13 11 15
Female 10 5 8 11 13 11 15 8
Mean age (years) 72.3 70.3 71.8 73.4 71.8 75.1 74.6 71.3
A, with acetazolamide; B, without acetazolamide.
work in animals [5] has shown that acetazolamide administra-
tion is effective in increasing the aqueous humor concentrations
of piperacillin but not of tobramycin. In the present study, we
tried to investigate whether the above finding could apply also
to the human eye by studying acetazolamide effects upon the
aqueous humor kinetics of four newer If-Iactams, namely
ceftazidime, cefotaxime, ceftriaxone and aztreonam, active
against multiresistant Gram-negative bacteria of nosocomial
ongm.
PATIENTS AND METHODS
One hundred and eighty-eight patients, 107 males and 81
females, undergoing eye cataract extraction were included in
this open randomized study, after giving oral informed consent.
Their age range was 47-92 years, mean 73.2 years. The cataracts
were classified as senile in 177, presenile in nine, and pathologic
in two. Excluded from the study were patients currently being,
or having been for the preceding 2 weeks, either locally
(ointments or eye solutions) or systemically treated with anti-
biotics for any reason, patients with renal failure (serum crea-
tinine > 1.5 mg/dL), liver insufficiency (serum ASTor ALT > 2
times upper normal limits), or known allergy to If-Iactams,
patients in poor general condition, and those not consenting.
Patients were randomized, according to a predetermined order
generated by using allocation tables, into four groups (I-IV),
according to the antibiotic given. Group I consisted of patients
receiving ceftazidime, group II of those receiving cefotaxime,
group III of those receiving ceftriaxone, and group IV of those
receiving aztreonam. Each group was further divided into two
subgroups according to whether acetazolamide was concur-
rently given (A) or not given (B).
The investigation was approved by the Hospital Ethics
Committee, and the research was carried out in accordance
with the Helsinki Declaration.
All antibiotics were given as a 30-min intravenous infusion of
two 2-g doses diluted into 100 mL of normal saline, 6 h
(ceftazidime), 8 h (cefotaxime, aztreonam) or 12 h (ceftriax-
one) apart, the last being administered at 2 h, 4 hand 6 h
(ceftriaxone also at 12 h, because of its greater half-life) before
the operation. Acetazolamide (subgroup A patients only) was
administered orally as three 250-mg doses at 6-h intervals, the
last dose being given 3 h before the scheduled time of opera-
tion, which is the anticipated time ofits peak concentration [6].
The demographic characteristics ofpatients allocated to each
group are shown in Table 1, while the numbers of patients
sampled at each time interval are shown in Table 2. Therefore,
randomization resulted in group construction without any
significant difference regarding patients' demographics.
Sampling of the aqueous humor was done through puncture
at the surgical corneoscleral limbus, using a fine needle and
syringe at the beginning of the operation and after local
anesthesia but before the incision was performed. Operative
field preparation was done using povidone iodine solution, and
the eye was washed with Balanced Salt Solution (BSS-Alcon
Couvrier SA, Purs, Belgium). No antibiotic-containing pre-
Table 2 Number of patients sampled at various time intervals after the last antibiotic administration
Group I (Ceftazidime) Group II (Cefotaxime) Group III (Ceftriaxone) Group IV (Aztreonam)
Time (h) A B A B A B A B
2 11 5 6 6 7 6 9 2
4 10 5 9 10 7 6 9 4
6 10 5 7 6 6 6 8 6
12 5 6
Total 31 15 22 22 25 26 26 23
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Table 3 Results of the effects of acetazolamide on aqueous humor kinetics of ceftazidime, cefotaxime, ceftriaxone and aztreonam in humans with non-inflamed eye
Group I: Ceftazidime (mg(L) Group II: Cefotaxime (mg(L) Group III: Ceftriaxone (mg(L) Group IV: Aztreonam (mg(L)
Time (h) A B A B A B A B
--
2
H 22.4 (± 16.6) 4.26 (± 1.75) 1.75(± 0.36) 1.11 (± 0.28) 1.76(± 0.39) 1.35 (± 0.11) 6.9 (± 1.26) 3.38 (± 0.83)
S 73.36 (± 47.5) 66.4 (± 24.8) 15.6 (± 1.57) 11.35 (± 2.84) 61.0(± 11.0) 52.67 (± 6.65) 55.11 (± 6.92) 49.37 (± 6.27)
R 0.30 0.06 0.11 0.10 0.03 0.025 0.12 0.06
H 16.4(± 9.2) 8.66 (± 5.49) 1.0(± 0.22) 0.81 (± 0.23) 1.49 (± 0.3) 0.95 (± 0.26) 5.64 (± 1.16) 2.57 (± 0.63)
4
S 38.5 (± 13.3) 51.8(± 11.9) 4.8 (± 0.77) 3.59 (± 0.72) 45.14(± 5.12) 42.33 (± 4.1) 33.66 (± 5.51) 26.12 (± 5.24)
R 0.43 0.17 0.22 0.225 0.033 0.022 0.17 0.1
H 8.6 (± 5.5) 5.61 (± 7.5) 0.77 (± 0.15) 0.58 (± 0.24) 1.57(± 0.34) 1.08 (± 0.23) 3.61 (± 0.49) 1.48 (± 0.3)
6
S 34.4 (± 14.9) 30.6 (± 30.5) 1.73(± 0.39) 1.88 (± 0.49) 40.16 (± 2.61) 48.0 (± 3.69) 27.31 (± 2.93) 21.0(± 3.4)
R 0.25 0.18 0.44 0.35 0.039 0.022 0.13 0.07
H ND ND ND ND 1.41 (± 0.42) 0.85 (± 0.16) ND ND
12
S ND ND ND ND 28.8 (± 5.72) 23.6 (± 2.0) ND ND
R ND ND ND ND 0.04 0.036 ND ND
H, mean aqueous humor concentration (± SD); S, mean serum concentration (± SD); R, corresponding ratios of H to S; A, with acetazolamide; B,without acetazolamide; ND, not done.
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paration was used on either eye before puncture. Local anesthe-
sia was obtained by truncal ipsilateral facial nerve blocking and
retrobulbar injection of 2% xylocaine and 0.5% marcaine
solutions. Puncture was performed at the superior part of
the sclerocorneal junction with a fine needle and syringe,
and the aqueous humor sample thus obtained was transferred
into a sterile container. A 5-mL venous blood sample was
simultaneously withdrawn. Serum was aseptically separated,
and both samples were kept at - 70°C until they were assayed.
Antibiotic assays were performed using an agar well diffusion
technique with Sensitivity Test Agar no. 2 (Gibco BRL, Paisley,
UK) and Escherichia coli 14 (ICB 4004) as indicator organism
[7].
Statistical analysis of the results was done using the paired
t-test.
RESULTS
Mean concentrations and standard deviations (SDs) in aqueous
humor (H) and serum (S) and the corresponding ratios (R) of
aqueous humor to serum concentrations for each group of
patients are shown in Table 3.
All aqueous humor concentrations achieved after acetazola-
mide administration were increased. Statistical significance was
obtained for ceftazidime at 2 h (P < 0.01) and 4 h (P < 0.05)
but not at 6 h, for cefotaxime at 2 h (P < 0.01) and 4 h
(P < 0.05) but not at 6 h, for ceftriaxone at 4 h (P < 0.01),
6 h (P < 0.05) and 12 h (P < 0.05), and for aztreonam at all
the intervals tested (P < 0.001).
DISCUSSION
Endophthalmitis remains a serious infection that threatens the
patients' vision and may lead to enucleation of the bulb.
Although new and potent antimicrobial agents with improved
pharmacokinetic properties have been developed during the last
few years, bacteria have already developed resistance mechan-
isms to them, and no alternatives, especially for Gram-negative
rods, are likely to be available in the near future. Such infections
are also more problematic to treat, since several of them are now
recognized to be caused by bacteria previously considered to be
non-pathogenic, such as Bacillus cereus and Propiobacterium ames,
some of which are also multiply resistant. The blood-eye
barriers further compromise the efficacy of systemic antibiotics,
necessitating their local administration in the form ofeye drops,
or as subconjunctival or parabulbar injections. The latter prac-
tice, although remaining the mainstay ofthe current therapeutic
approach, has limited usefulness, since pain and local irritation,
as well as local toxicity problems, usually make impossible the
repetition of this form of administration as often as needed.
Direct intravitreous injection of antibiotics is currently
being used together with locally applied antibiotics for treating
postoperative endophthalmitis in order to achieve higher anti-
biotic concentrations within the inflamed eye. Vitrectomy,
according to the results of a recently published large trial, must
be reserved for patients not responding to conservative therapy
within 36-60 h or for those presenting with only light percep-
tion [8]. From the same study, it was also concluded that
systemically administered ceftazidime-amikacin is of limited
benefit, and the decision regarding its administration must be
based on clinical judgment. One solution would be to find ways
of improving the use of the currently existing antibiotics in
order to maximize the expected benefit of their systemic use in
the therapy of serious intraocular infections.
Previous work in animals [5] has shown that co-administra-
tion of acetazolamide could result in a clinically significant
increase ofthe aqueous humor concentration ofpiperacillin but
not of tobramycin. Change of the intraocular pH and/or
dehydration of the bulb caused by acetazolamide, in addition
to its physicochemical properties, and especially the electrical
charges of the individual antibiotics, are offered as possible
explanations ofthese effects. In the present study, the possibility
ofthe extension of this effect to the human eye was explored by
studying the effects of acetazolamide upon the eye pharmaco-
kinetics of four newer If-lactams, namely ceftazidime, cefotax-
ime, ceftriaxone and aztreonam, which were selected to be
studied because of their broad spectrum of activity, which
permits therapy of nosocomial infections.
Human steady-state pharmacokinetic studies of ceftazidime
in 11 patients after three I-g intramuscular doses disclosed mean
aqueous humor levels of 3.3-1.2 mg/L 2-6 h later [9], while
similar levels have been reported (3.39-1.94 mg/L, 0.5-6 h)
after a single 2-g intravenous dose [10]. In the present study,
levels substantially higher, most evident at 4 h and especially
6 h, were obtained for our patients in the non-acetazolamide
(group IB , ceftazidime) group, and this has to be attributed to
the route and the larger dose administered. Acetazolamide
resulted in statistically significantly higher levels at 2 and 4 h
that exceeded even ceftazidime's susceptibility cut-off point for
P aeruginosa (16 mg/L). Since the ratio of aqueous humor to
serum concentrations increased 2-6-fold, one has to consider
this as a specific effect of acetazolamide upon the eye and not
just a consequence of higher serum levels.
Studies of cefotaxime pharmacokinetics in humans showed
that intramuscular injection of 1 g (in 25 people) resulted in
undetectable aqueous humor levels, while subconjunctival
injection of 100 mg in the same patients resulted in detectable
levels only in those who were lenseless or had undergone
vitrectomy [11]. Intravenous administration of three 1- or 2-
g doses in patients undergoing eye cataract surgery resulted in
mean maximum aqueous humor concentrations of 1.85 mg/L
and 3.8-3.95 mg/L [9,12], respectively, obtained about 2 h
later, and administration of 2 g, intravenously, 2 h before
vitrectomy in mean intravitreal concentrations of 0.95 mg/L
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[13]. The observed difference must reflect the higher cefotax-
ime serum levels obtained after intravenous administration.
These results are in accordance with that for our group lIB
(cefotaxime) patients. Although acetazolamide resulted in sta-
tistically significantly higher aqueous humor concentrations of
cefotaxime at 2 and 4 h, from the clinical point of view these
had to be considered negligible, the observed rise being attrib-
uted to the higher resulting corresponding serum levels, since
the ratio of aqueous humor to serum concentrations remained
mostly unchanged.
Intravenous administration of ceftriaxone in humans did not
produce detectable levels [14] after three 1-g doses, although the
authors could not exclude the possibility that this could be
ascribed to the assay they applied. In the present study, low
levels, but still useful for treating infections due to highly
susceptible pathogens, e.g. enterobacteriaceae, were found even
in patients not receiving acetazolamide. The latter had a
statistically significant effect upon ceftriaxone aqueous humor
concentrations. From the clinical point of view, this could be
considered indicative of some benefit, since it resulted in
prolongation of ceftriaxone persistence in this compartment,
so that concentrations at 4, 6 and 12 h were kept close to those
at 2 h. The mechanism of this effect remained obscure, since
inconsistent changes in the aqueous humor to serum ratios were
found.
Studies of aztreonam kinetics in human eye [15] revealed
mean aqueous humor levels, 1-4 h after a 2-g intravenous
infusion, of 1.22-2.22 mg/L. These levels far exceeded the
MICs for most Enterobacteriaceae, with the exception of
Enterobacter spp., but not that of Pseudomonas aeruginosa. In
the present study, acetazolamide resulted in a more than dou-
bling of aztreonam aqueous humor concentrations that was
statistically significant at all the intervals tested and could be of
clinical relevance.
Although the anterior chamber is not representative of the
other eye compartments, it can be considered the most crucial,
since at least some of the intraocular infections that start there,
such as those resulting from corneal trauma or those associated
with eye cataract surgery, can, with prompt treatment, be
confined there. From the clinical point of view, our findings
suggest that the increase in aqueous humor concentrations
obtained by acetazolamide co-administration can be considered
relevant mostly for ceftazidime and perhaps for aztreonam
and ceftriaxone, the effect on the latter being more prominent
for the delayed concentrations, and entirely irrelevant for
cefotaxime.
Taking into account the fact that in order for there to be a
beneficial effect, an antibiotic's level at the site ofinfection has to
exceed the antibiotic's MIC for the pathogen isolated, the
present study identified a clinically significant benefit from
acetazolamide co-administration ouly for ceftazidime and not
with any of the remaining three If-lactams. The different
behavior of ceftazidime is difficult to explain. A possible
explanation might be that the position 3 substitute of ceftazi-
dime, being highly polar, is greatly influenced, according to the
Henderson-Hasselbach equation, by the aqueous humor pH
shift produced by acetazolamide, resulting in a delay in its
aqueous humor clearance, in a similar way to that suggested
for piperacillin [5]. However, it must be taken into account that
the present study was performed in non-inflamed eyes, and the
above results may not apply to already inflamed eyes, where eye
barriers are destroyed.
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